Alpine Immune Sciences Inc (NASDAQ: ALPN) stock price fell over 1.3% intraday today, following the Q4 results, which were below expectations. Despite this setback, Alpine is optimistic about its progress with povetacicept, a potential best-in-class dual BAFF/APRIL inhibitor for multiple autoantibody-related diseases. Alpine recently initiated the RUBY-3 study in autoimmune glomerulonephritis and is expected to begin the RUBY-4 study in autoimmune cytopenias, with updates anticipated by year-end. Dr. James Tumlin expressed his excitement about the RUBY-3 study and the potential for povetacicept to be a “potent disease-modifying therapy.” Alpine’s strong balance sheet and povetacicept’s promising preclinical and phase 1 healthy volunteer data are driving the company’s robust development plan, which could bring new therapeutic options for patients living with various autoimmune or inflammatory diseases. The unique, convenient subcutaneous dosing regimen every four weeks of povetacicept could provide an advantage over other therapies.
Alpine Immune Sciences Inc (NASDAQ: ALPN) experienced a drop of over 1.3% in its stock price intraday today, attributed to its Q4 results. The company reported a Q4 EPS of ($0.41), which is $0.15 lower than a consensus of ($0.26), and revenue of $2.78 million, which is below the consensus of $10.96 million. Despite this setback, Alpine’s executive chairman and CEO, Mitchell Gold, remains optimistic about the company’s progress. He stated, “2023 is on track to be a pivotal year for Alpine and povetacicept, a potential best-in-class dual BAFF/APRIL inhibitor which we are developing for multiple autoantibody-related diseases.” Alpine has recently initiated the RUBY-3 study in autoimmune glomerulonephritis and is expected to begin the RUBY-4 study in autoimmune cytopenias. Dr. James Tumlin, founder and medical director of the NephroNet Clinical Trials Consortium, expressed his excitement about the RUBY-3 study and the potential for povetacicept to be a “potent disease-modifying therapy.” The study will focus on autoimmune glomerulonephritis, particularly IgA nephropathy, which can lead to renal failure if untreated. Alpine’s strong balance sheet and povetacicept’s promising preclinical and phase 1 healthy volunteer data are driving the company’s robust development plan, which could bring new therapeutic options for patients living with various autoimmune or inflammatory diseases. The unique, convenient subcutaneous dosing regimen every four weeks of povetacicept could provide an advantage over other therapies. The company anticipates sharing updates on both studies by the end of the year.
Don’t miss interesting posts on Famousbio
